Company news

Cardiff Oncology, Inc. news in 2024

Cardiff Oncology, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

December 9, 2024

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

December 9, 2024

Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC

November 18, 2024

Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

November 6, 2024

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

October 29, 2024

Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update

August 7, 2024

Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update

July 31, 2024

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 28, 2024

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 12, 2024

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

May 1, 2024

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

April 24, 2024

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

April 7, 2024

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

March 5, 2024

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

February 28, 2024

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

February 28, 2024

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

February 28, 2024

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

February 25, 2024

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

February 21, 2024

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

January 16, 2024

Calls in 2024

Decks in 2024